Varda Shalev - 05 Jun 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Director
Signature
/s/ Dov Bergwerk as attorney-in-fact for Varda Shalev
Issuer symbol
TEVA
Transactions as of
05 Jun 2025
Net transactions value
$0
Form type
4
Filing time
09 Jun 2025, 16:20:39 UTC
Previous filing
04 Sep 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shalev Varda Director C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL /s/ Dov Bergwerk as attorney-in-fact for Varda Shalev 09 Jun 2025 0001873934

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +9,632 +75% 22,504 06 Jun 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -9,632 -100% $0.000000 0 06 Jun 2025 Ordinary Shares 9,632 Direct F1, F2, F3
transaction TEVA Restricted Share Units Award $0 +14,492 $0.000000 14,492 05 Jun 2025 Ordinary Shares 14,492 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.
F4 Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.